KaydedilenlerDerginizi ekleyin

Dergiler / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 3

Apixaban successfully resolved a warfarinresistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis

Yae Min Park
Jeonggeun MOON
Wook Jin CHUNG
Mi Seung SHIN
In Suck CHOI
Sayfa
174–175
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Here, we report the case of a patient with paroxysmal AF and end-stage renal disease (ESRD) requiring hemodialysis, in whom apixaban successfully and safely resolved a LAAthrombus refractory to warfarin.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The left atrial appendage (LAA) is the major source of thromboembolism in patients with atrial fibrillation (AF).
📊
Temel Bulgular & Veri:Warfarin ornew oral anticoagulants (NOACs) have been used to treat the LAAthrombus; however, the use of NOACs is limited in patients withrenal dysfunction.
💡
Sonuç & Katkı:Here, we report the case of a patient with paroxysmal AF and end-stage renal disease (ESRD) requiring hemodialysis, in whom apixaban successfully and safely resolved a LAAthrombus refractory to warfarin.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

The left atrial appendage (LAA) is the major source of thromboembolism in patients with atrial fibrillation (AF). Warfarin ornew oral anticoagulants (NOACs) have been used to treat the LAAthrombus; however, the use of NOACs is limited in patients withrenal dysfunction. Here, we report the case of a patient with paroxysmal AF and end-stage renal disease (ESRD) requiring hemodialysis, in whom apixaban successfully and safely resolved a LAAthrombus refractory to warfarin.

🔖

Bu Makaleye Atıf Yap

Park, Y. M., MOON, J., CHUNG, W. J., SHIN, M. S., CHOI, I. S. (2019). Apixaban successfully resolved a warfarinresistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 3, 174–175. https://ajindex.com/articles/365747

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (7)

  1. Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J 2017; 184: 37-46
  2. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628-36
  3. Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016; 56: 637-45
  4. Sarratt SC, Nesbit R, Moye R. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease. Ann Pharmacother 2017; 51: 445-50
  5. Kufel WD, Zayac AS, Lehmann DF, Miller CD. Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis. Pharmacotherapy 2016; 36: e166-71
  6. Miwa Y, Minamishima T, Sato T, Sakata K, Yoshino H, Soejima K. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban. J Arrhythm 2016; 32: 233-5
  7. Yanıkoğlu A, Altıntaş MS, Ekinözü İ. Dissolution of an apical thrombus by apixaban in a patient with old anteroseptal myocardial infarction. Anatol J Cardiol 2015; 15: 671-2.